| Clinical data | |
|---|---|
| Other names | SC-14266 |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal and fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.016.868 |
| Chemical and physical data | |
| Formula | C22H29KO4 |
| Molar mass | 396.568 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Potassium canrenoate (INN,JAN) orcanrenoate potassium (USAN) (brand namesVenactone,Soldactone), also known asaldadiene kalium,[1] thepotassiumsalt ofcanrenoic acid, is analdosterone antagonist of thespirolactone group.[2] Likespironolactone, it is aprodrug, and ismetabolized to activecanrenone in the body.[3][4]
Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available forparenteraladministration (specificallyintravenous)[4][5] as opposed tooral administration.[6]
In the UK, it is unlicensed and only used for short term diuresis in oedema or heart failure in neonates or children under specialist initiation and monitoring.
Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |